FemPulse Pioneers On Multiple Fronts
This article was originally published in Start Up
Executive Summary
Medtech start-up FemPulse is pursuing a novel neuromodulation approach to treating overactive bladder. START-UP talks to founder and president Alexandra Haessler MD, herself something of a novelty in the mostly-male world of medtech entrepreneurship.
You may also be interested in...
Neuromodulation Devices Stimulate Opportunities In Urology
Neuromodulation for urological indications, notably overactive bladder (OAB), has been dominated since the late 1990s by Medtronic’s sacral-nerve stimulation system InterStim, with the more recent addition of Cogentix Medical’s Urgent PC for tibial nerve stimulation. Yet only a fraction of OAB patients receive effective neuromodulation treatment, and several companies hope to lower barriers to this modality by developing alternative devices for urological indications.
Why Investing In ESG Measures Is Good For Medtech’s Health And Sustainability
For medtechs, implementing an ESG strategy will need to become a priority as global rules are being introduced for companies to report ESG data. A panel discussion with medtech ESG leaders at the recent LSX Congress USA conference in Boston outlined some strategies and sustainability goals.
Lilly Looks To Take POINT On Emerging Cancer Radiopharmaceutical Space
Lilly has agreed to pay $1.4bn to acquire Point even though the company’s two lead candidates are out-licensed to Lantheus. The deal looks like an early-stage play to build a strong position in an emerging field.